[Form 4] COLGATE PALMOLIVE CO Insider Trading Activity

Rhea-AI Filing Summary

Jennifer Daniels, Chief Legal Officer and Secretary of Colgate-Palmolive Company (CL), reported equity awards granted on 09/11/2025. The filing shows a non-derivative acquisition of 4,592 common stock units (restricted stock units) at $0.00, leaving 77,980 shares directly beneficially owned after the transaction, plus 1,813 indirectly owned through the issuer's 401(k) plan trustee. The filing also reports a stock option award with an $84.06 exercise price for 31,796 options, exercisable in equal annual installments over three years beginning on the first anniversary of the 09/11/2025 grant and expiring 09/11/2033. The RSUs vest in three equal annual installments from the grant date. The form is signed by an attorney-in-fact on 09/12/2025.

Insights

Corporate Governance Expert

TL;DR: Routine executive equity grants consistent with long-term incentive practices.

The reported transactions are standard incentive awards: restricted stock units and time-based stock options issued to a named executive (CLO and Secretary). The RSUs vest in equal thirds over three years and the option vests annually over three years, which aligns with common retention-focused designs. The option exercise price is set at $84.06 and the awards increase the reporting person's direct holdings by specified amounts, strengthening executive alignment with shareholders without indicating extraordinary or ad hoc compensation practices in this filing alone.

Compensation Analyst

TL;DR: Materiality limited to compensation disclosure; no immediate cash proceeds or dispositions reported.

This Form 4 documents grant-date awards rather than sales or purchases for cash. The director/officer received 4,592 RSUs and 31,796 options at an $84.06 strike, which are customary equity-based pay elements. Vesting schedules tied to multi-year service suggest retention intent. Because the document reports increases in beneficial ownership rather than dispositions, it does not reflect monetization events or insider selling.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Daniels Jennifer

(Last) (First) (Middle)

C/O COLGATE-PALMOLIVE COMPANY

300 PARK AVENUE

(Street)

NEW YORK NY 10022

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
COLGATE PALMOLIVE CO [ CL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CLO and Secretary

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/11/2025		A(1)		4,592	A	$0.0000	77,980	D
Common Stock								1,813	I	By Issuer's 401(k) Plan Trustee

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$84.06	09/11/2025		A(2)		31,796		(3)	09/11/2033	Common Stock	31,796	$0.0000	31,796	D

Explanation of Responses:

1. Restricted stock unit award granted under the issuer's incentive compensation plan. The restricted stock unit award vests in equal 1/3 installments on each of the first, second and third anniversary of the date of grant.

2. Stock option award granted under the issuer's incentive compensation plan.

3. Option becomes exercisable in equal annual installments over three years beginning on the first anniversary of the September 11, 2025 grant date.

	/s/ Kristine Hutchinson, Attorney-in-Fact	09/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.